Want to see APVO full AI Analyst Report?
Aptevo Therapeutics (APVO) Stock Statistics & Valuation Metrics
Total Valuation
Aptevo Therapeutics has a market cap or net worth of $2.24M. The enterprise value is -$276.14K.
- Market Cap
- $2.24M
- Enterprise Value
- -$276.14K
Share Statistics
Aptevo Therapeutics has 1,810,215 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,810,215
- Owned by Insiders
- 0.37%
- Owned by Institutions
- 1.84%
Financial Efficiency
Aptevo Therapeutics’s return on equity (ROE) is -1.49 and return on invested capital (ROIC) is -119.55%.
- Return on Equity (ROE)
- -1.49
- Return on Assets (ROA)
- -0.95
- Return on Invested Capital (ROIC)
- -119.55%
- Return on Capital Employed (ROCE)
- -1.24
- Revenue Per Employee
- 0
- Profits Per Employee
- -786.88K
- Employee Count
- 33
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Aptevo Therapeutics is -0.01. Aptevo Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 0.00
- PB Ratio
- 0.25
- Price to FCF
- -0.11
- Price to Operating Cash Flow
- -0.06
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Aptevo Therapeutics had revenue of 0 and earned -25.97M in profits. Earnings per share was -87.27.
- Revenue
- 0
- Gross Profit
- -240.00K
- Operating Income
- -26.31M
- Pretax Income
- -25.97M
- Net Income
- -25.97M
- EBITDA
- -25.73M
- Earnings Per Share (EPS)
- -87.27
Cash Flow
In the last 12 months, operating cash flow was -25.34M and capital expenditures 0, giving a free cash flow of -25.34M billion.
- Operating Cash Flow
- -25.34M
- Free Cash Flow
- -25.34M
- Free Cash Flow per Share
- -21.18
Dividends & Yields
Aptevo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -934.58%
- Earnings Yield
- -1780.12%
Stock Price Statistics
- Beta
- 0.09
- 52-Week Price Change
- -95.31%
- 50-Day Moving Average
- 1.73
- 200-Day Moving Average
- 4.08
- Relative Strength Index (RSI)
- 24.51
- Average Volume (3m)
- 99.04K
Important Dates
Aptevo Therapeutics upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Aptevo Therapeutics as a current ratio of 3.82, with Debt / Equity ratio of 26.63%
- Current Ratio
- 3.82
- Quick Ratio
- 3.82
- Debt to Market Cap
- 16.59
- Net Debt to EBITDA
- 0.66
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Aptevo Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Aptevo Therapeutics EV to EBITDA ratio is 0.11, with an EV/FCF ratio of 0.11.
- EV to Sales
- 0.00
- EV to EBITDA
- 0.11
- EV to Free Cash Flow
- 0.11
- EV to Operating Cash Flow
- 0.11
Balance Sheet
Aptevo Therapeutics has $9.80M in cash and marketable securities with $4.21M in debt, giving a net cash position of $5.59M billion.
- Cash & Marketable Securities
- $9.80M
- Total Debt
- $4.21M
- Net Cash
- $5.59M
- Net Cash Per Share
- $3.09
- Tangible Book Value Per Share
- $5.05
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Aptevo Therapeutics is $21.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $21.00
- Price Target Upside
- 1593.55% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 99.41%
Scores
- Smart Score
- ―
- AI Score
- 45
